RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average recommendation of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $9.56.

Several research firms recently commented on RAPT. Stifel Nicolaus restated a “hold” rating and set a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company dropped their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. HC Wainwright upgraded shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday, December 26th. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Finally, JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th.

RAPT Therapeutics Stock Performance

RAPT stock opened at $1.32 on Friday. The firm has a market cap of $46.14 million, a PE ratio of -0.48 and a beta of 0.07. The firm’s fifty day moving average is $1.43 and its 200 day moving average is $2.05. RAPT Therapeutics has a one year low of $0.79 and a one year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. Research analysts predict that RAPT Therapeutics will post -2.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its position in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares during the last quarter. Readystate Asset Management LP acquired a new position in RAPT Therapeutics during the third quarter worth about $36,000. Barclays PLC boosted its holdings in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after purchasing an additional 29,195 shares during the last quarter. XTX Topco Ltd acquired a new position in RAPT Therapeutics in the 2nd quarter valued at about $108,000. Finally, Exchange Traded Concepts LLC boosted its holdings in RAPT Therapeutics by 244.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock valued at $179,000 after purchasing an additional 63,235 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.